Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Sep has averaged the highest return (+10.4%); Feb the lowest (-9.0%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.7%Negative MonthJan 2026: -12.69% | +4.0%Positive MonthFeb 2026: +3.99% | -16.8%Negative MonthMar 2026: -16.84% | +12.2%Positive MonthApr 2026: +12.23% | +1.2%Neutral MonthMay 2026: +1.20% | +10.8%Positive MonthJun 2026: +10.75% | -1.9%*Neutral MonthJul 2026: -1.85% | β | β | β | β | β |
| 2025 | -1.7%Neutral MonthJan 2025: -1.75% | -31.2%Negative MonthFeb 2025: -31.16% | +12.1%Positive MonthMar 2025: +12.12% | -9.1%Negative MonthApr 2025: -9.07% | +14.6%Positive MonthMay 2025: +14.58% | +5.9%Positive MonthJun 2025: +5.86% | -4.2%Negative MonthJul 2025: -4.23% | -5.0%Negative MonthAug 2025: -5.05% | -2.0%Neutral MonthSep 2025: -1.98% | -12.5%Negative MonthOct 2025: -12.46% | -1.6%Neutral MonthNov 2025: -1.55% | -5.3%Negative MonthDec 2025: -5.27% |
| 2024 | -1.0%Neutral MonthJan 2024: -1.02% | +0.2%Neutral MonthFeb 2024: +0.17% | +4.4%Positive MonthMar 2024: +4.42% | +8.9%Positive MonthApr 2024: +8.92% | -11.7%Negative MonthMay 2024: -11.70% | +5.7%Positive MonthJun 2024: +5.74% | +6.0%Positive MonthJul 2024: +5.97% | +1.5%Neutral MonthAug 2024: +1.49% | +21.9%Positive MonthSep 2024: +21.93% | -9.5%Negative MonthOct 2024: -9.51% | +15.7%Positive MonthNov 2024: +15.67% | +4.1%Positive MonthDec 2024: +4.06% |
| 2023 | β | β | β | β | β | β | β | β | +11.3%Positive MonthSep 2023: +11.32% | +6.0%Positive MonthOct 2023: +5.98% | +16.4%Positive MonthNov 2023: +16.35% | +10.0%Positive MonthDec 2023: +9.97% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 4 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.20 K Cr | β | βΉ373.00 Cr | β | β | 20.6% | 18.0% | 22.3% |
| Mar 2024 | βΉ1.02 K Cr | β | βΉ305.00 Cr | β | β | 20.0% | 19.2% | 28.2% |
| Mar 2023 | βΉ853.00 Cr | β | βΉ238.00 Cr | β | β | 18.4% | 19.6% | 33.0% |
| Mar 2022 | βΉ713.00 Cr | β | βΉ179.00 Cr | β | β | 16.2% | 15.6% | -23.8% |
| Mar 2021 | βΉ617.00 Cr | β | βΉ235.00 Cr | β | β | 23.5% | 20.5% | 39.1% |
| Mar 2020 | βΉ512.00 Cr | β | βΉ169.00 Cr | β | β | 21.9% | 17.4% | 43.2% |
| Mar 2019 | βΉ436.00 Cr | β | βΉ118.00 Cr | β | β | 17.3% | 28.2% | 18.0% |
| Mar 2018 | βΉ340.00 Cr | β | βΉ100.00 Cr | β | β | 16.8% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 340 | 436 | 512 | 617 | 713 | 853 | 1,017 | 1,200 | 1,125 |
| Total Expenses | 195 | 256 | 308 | 289 | 439 | 509 | 585 | 693 | 685 |
| EBIT / Operating Profit | 145 | 180 | 205 | 328 | 274 | 344 | 432 | 507 | 440 |
| OPM % | 43% | 41% | 40% | 53% | 38% | 40% | 42% | 42% | 39% |
| Other Income | 18 | 17 | 31 | 14 | 23 | 35 | 34 | 44 | 51 |
| Finance Costs | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 1 | 0 |
| Depreciation & Amortisation | 18 | 19 | 21 | 28 | 50 | 54 | 54 | 54 | 64 |
| Profit Before Tax | 144 | 178 | 213 | 313 | 241 | 320 | 409 | 496 | 427 |
| Tax % | 30% | 33% | 21% | 25% | 26% | 26% | 26% | 25% | - |
| Net Profit / PAT | 100 | 118 | 169 | 235 | 179 | 238 | 305 | 373 | 322 |
| EPS (βΉ) | 105.66 | 124.48 | 177.65 | 247.44 | 187.76 | 22.76 | 29.13 | 35.65 | 30.73 |
| Dividend Payout % | 0% | 21% | 22% | 0% | 3% | 30% | 30% | 25% | - |
Peer Comparison
Technology sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Concord Biotech Limitedthis co. | βΉ14.12 K Cr | βΉ1.20 K Cr | 43.90 | 7.77 | 30.04 | 18.0% |
| Bharti Airtel Ltd. | βΉ12.19 L Cr | βΉ1.09 L Cr | 50.40 | 8.31 | 27.19 | 15.8% |
| Tata Consultancy Services Ltd. | βΉ11.84 L Cr | βΉ2.15 L Cr | 24.20 | 13.91 | 18.91 | 6.2% |
| Infosys Ltd | βΉ6.48 L Cr | βΉ1.37 L Cr | 24.20 | 7.17 | 16.31 | 5.9% |
| HCL Technologies Ltd | βΉ4.52 L Cr | βΉ51.10 K Cr | 36.80 | 14.48 | β | 6.2% |
| Bharat Electronics Ltd. | βΉ3.02 L Cr | βΉ23.66 K Cr | 53.30 | 14.23 | 51.32 | 17.3% |
| Wipro Ltd. | βΉ2.77 L Cr | βΉ67.29 K Cr | 23.00 | 4.29 | 18.85 | 0.8% |
| Industry Average | β | βΉ10.05 K Cr | 69.99 | 8.58 | 66.75 | 22.0% |
